Generic versions of the major drug Eliquis are already being marketed in some EU countries, impacting current international revenue. The company faces a US patent cliff in 2028 after settling litigation, creating long-term pressure to optimize costs and find replacement revenue streams.
Filing excerpt
For Eliquis, in the U.S., multiple generic companies challenged patents... Under the terms of previously executed settlement agreements, the generic companies with whom BMS settled are permitted to launch in 2028...
What this signalsFilings often name leadership changes, deals and spending plans.
Vendors
Regions named
sec-10krestructuringGet every 10-K signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/54a9cf0d-24b1-47d2-8c42-d81100ff13eb returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.
{
"signal_id": "54a9cf0d-24b1-47d2-8c42-d81100ff13eb",
"signal_type": "sec-10k",
"signal_subtype": "restructuring",
"detected_at": "2026-02-17T06:30:02.078+00:00",
"company": {
"name": "Bristol Myers Squibb",
"domain": "bms.com"
},
"data": {
"detail": "Generic versions of the major drug Eliquis are already being marketed in some EU countries, impacting current international revenue. The company faces a US patent cliff in 2028 after settling litigation, creating long-term pressure to optimize costs and find replacement revenue streams.",
"metrics": {
"timeframe": "multi_year"
},
"summary": "Generics erode Eliquis sales in the EU; US market faces patent cliff in 2028",
"excerpts": "For Eliquis, in the U.S., multiple generic companies challenged patents... Under the terms of previously executed settlement agreements, the generic companies with whom BMS settled are permitted to launch in 2028...",
"relevance": 0.9,
"sentiment": "negative",
"confidence": "medium",
"source_url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm",
"filing_date": "2026-02-11",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Change management needs",
"signal_category": "workforce",
"regions_mentioned": [
"U.S.",
"EU"
],
"vendors_mentioned": [
"Pfizer"
]
}
}
curl https://signals.autobound.ai/v1/signals/54a9cf0d-24b1-47d2-8c42-d81100ff13eb \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bms.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.